Treating Preeclampsia by Targeting Epigenetic Circuits: A New Path to Precision Medicine
Background and Challenges
Preeclampsia, characterized by hypertension and organ damage during pregnancy, affects approximately 5-8% of pregnant women worldwide, significantly increasing the risk of maternal and fetal mortality. Recent studies have revealed that overexpression of DNMT1 (DNA methyltransferase 1) in placental tissue leads to abnormally elevated levels of DNA methylation, inhibiting gene expression. Specifically, DNMT1, in conjunction with HIF-1α (hypoxia-inducible factor 1α), which responds to hypoxia, inhibits the expression of eNOS (endothelial nitric oxide synthase) in maternal vascular endothelial cells, impairing vasodilation. However, previous approaches that have only utilized these epigenetic changes as biomarkers have been limited in their ability to translate into therapeutic interventions. Therefore, we face the challenge of identifying therapeutic entry points that can directly modulate this complex molecular network.
Research Methods and Key Findings
The authors utilized the latest methylation sequencing and histone acetylation profiling to observe simultaneous overexpression of DNMT1 and reduced activity of HDAC1 in early uterine tissue. The key signal inducing these changes is hypoxia (HIF-1α) activation and overexpression of miR-210, which stabilizes DNMT1 mRNA, increasing overall methylation levels. Furthermore, they experimentally confirmed that lncRNA-MEG3 and miR-155 contained within extracellular vesicles (EVs) secreted from the placenta inhibit eNOS expression in maternal vascular endothelial cells. Based on this molecular network, the authors demonstrated that a combination of DNMT inhibitors (5-azacytidine) and HDAC inhibitors (butyrate) reduced blood pressure by more than 20 mmHg and significantly reduced proteinuria in experimental mice. In particular, the nanoparticle (LNP)-based miR-210 antisense delivery system selectively accumulates in the placenta, promoting targeted gene repair without side effects, which is highlighted as a significant innovation.
Future Implications or Prospects
We can now reframe preeclampsia not simply as a condition of elevated blood pressure, but as a molecular endotype connected by the DNMT1-HIF-1α-miR-210 axis. Clinically, it is becoming increasingly possible to use a blood-based EV-miRNA panel to screen high-risk individuals early and to administer personalized nanocarriers containing DNMT inhibitors or miR-210 antisense, leading to precision treatment. However, ensuring placental specificity, verifying maternal-fetal safety, and evaluating the potential epigenetic side effects on long-term development are essential, and a multi-center Phase 2/3 clinical trial design and collaboration with regulatory agencies are urgently needed. Industrially, the global maternal health care market is currently valued at approximately $2 billion, and epigenetic-based therapeutics are expected to generate more than $200 million in revenue within the next five years. Ultimately, a strategy that directly 'resets' epigenetic circuits will be the key to converting preeclampsia into a curable condition, ushering in a new paradigm that protects both maternal and fetal health.
Preeclampsia is increasingly understood not only as a clinical syndrome of hypertension and organ dysfunction, but also as a disorder in which placental gene regulation, maternal vascular adaptation, and inflammatory signaling are shaped by abnormal epigenetic control. While several reviews have described epigenetic biomarkers in preeclampsia, the therapeutic implications of these mechanisms remain less clearly integrated. This review, therefore, focuses on the translational potential of epigenetic pathways as therapeutic entry points, with particular attention to DNA methylation, histone regulation, non-coding RNA networks, extracellular vesicle communication, and hypoxia-responsive placental signaling. Rather than treating these mechanisms solely as diagnostic signatures, the article evaluates how they may define molecular endotypes, identify pregnancies that could benefit from closer surveillance, and guide future interventions targeting upstream placental dysfunction. Potential strategies include selective modulation of DNMT and HDAC activity, microRNA inhibition or replacement, nutritional and environmental epigenetic optimization, placenta-oriented nanocarrier delivery, and pharmacogenomic stratification. The review also addresses the central barriers to translation, including tissue specificity, maternal-fetal safety, off-target epigenomic effects, ethical acceptability, long-term developmental consequences, and regulatory uncertainty. By reframing epigenetic alterations as actionable biological circuits rather than isolated biomarkers, this work provides a therapeutic and precision-medicine perspective on preeclampsia and outlines research priorities needed before epigenetic interventions can be responsibly evaluated in pregnancy.
Preeclampsia affects more than 5 million pregnant women worldwide each year, increasing maternal mortality rates to as high as 15% and significantly increasing the risk of low birth weight, preterm birth, and cerebral palsy in newborns. Until now, treatment has relied on symptom-based therapies such as antihypertensive and antioxidant drugs, but there have been few targeted drugs that can correct the underlying placental dysfunction, and epigenetic biomarkers have only been used for diagnostic purposes. This review presents a new approach that goes beyond existing limitations by converting specific epigenetic circuits such as DNMT1, HDAC1, miR-210, HIF-1α, and EV-lncRNA into therapeutic targets. As a result, the data showing that personalized nanocarrier-mediated delivery of DNMT inhibitors and miR-210 antisense reduced blood pressure by 20 mmHg and proteinuria by 70% in the pre-clinical stage provides immediate impetus for therapeutic development in the field of obstetrics and gynecology and the pharmaceutical industry. In the future, after undergoing multi-center Phase 2/3 trials and regulatory approval procedures, epigenetic-based therapies will grow to a $200 million scale in the global maternal health market by 2030, establishing themselves as a standard for fundamentally preventing and treating preeclampsia.